How Long Does Emgality (Galcanezumab) Take to Work?

How Long Does Galcanezumab Actually Take to Work?

If you just gave yourself your first Emgality injection and are wondering when something is going to happen, here is the answer: many patients notice fewer migraine days within the very first month, but the full benefit usually builds gradually over three to six months. Starting with the 240 mg loading dose (two injections at once) is designed to get the drug to meaningful levels in your body faster, which is why some people feel a difference sooner than others.

Clinical trials called EVOLVE-1 and EVOLVE-2 found statistically significant reductions in monthly migraine days as early as the first treatment period. A smaller number of patients report noticing improvement within days of that loading dose, though that early response is not the norm and may partly reflect the natural up-and-down rhythm of migraine cycles.

What Happens Month by Month After Your First Injection?

Understanding the rough timeline helps you interpret what you are feeling and avoid giving up too soon.

• Month 1: Both partial and full responders often show an early signal. You may not hit a dramatic reduction yet, but most people who will respond have at least a hint of improvement here.
• Months 2 to 3: The drug reaches steady-state concentration (a stable level in your bloodstream). Response rates and the size of the reduction typically improve during this window.
• Months 4 to 6: This is the peak therapeutic benefit window. If galcanezumab is going to work well for you, the evidence is usually clear by now.
• Beyond month 3 with zero change: A conversation with your neurologist about reassessment is reasonable. Continuing indefinitely without any signal is not the recommended path.

Tracking this progression is hard to do from memory alone. A headache diary, even a simple one on your phone, makes the month-by-month pattern visible.

Does the Loading Dose Actually Speed Things Up?

Yes, and the reason is pharmacokinetic (related to how the drug moves through your body), not just marketing. The 240 mg loading dose front-loads your exposure to galcanezumab, saturating the CGRP receptors (proteins that play a central role in triggering migraine pain) more quickly than starting at the 120 mg maintenance dose alone.

Comparative drug-level data suggest the loading dose achieves near-steady-state blood levels roughly one month sooner than skipping it. That is a meaningful head start when you are already managing a condition that disrupts your life every few weeks.

A few practical notes worth knowing:

• Not every prescriber uses the loading dose. Ask your provider whether you received it and how that affects your expected timeline.
• Cluster headache dosing is different. For cluster headache, galcanezumab is given as 300 mg monthly injections during the active cluster period, not the episodic migraine schedule.
• Extra doses will not help. There is no evidence that shortening the injection interval or taking additional doses speeds the response, and doing so is not approved.

CGRP Monoclonal Antibodies Compared

Galcanezumab is one of four approved CGRP monoclonal antibodies (biologic drugs that target the CGRP pathway). Here is how they compare on factors that matter when you are thinking about onset.

If speed of onset is your top priority and your insurance covers it, the intravenous option offers the fastest pharmacological start. However, it requires an infusion clinic visit every three months rather than a home injection.

Why Does Response Vary So Much Between Patients?

Two people can follow identical injection schedules and have completely different experiences. Several factors drive that variability.

Biological differences in how active your CGRP pathway is mean some people are simply stronger responders to this class of medication. That is not something you can control or predict in advance.

Baseline migraine frequency matters too. If you have 15 or more migraine days per month, a 50% reduction is dramatic and easy to notice. If you have 4 or 5 days per month, the same proportional improvement may feel subtler even when it is real.

Prior preventive treatments can also influence your response. Having tried and not responded to another CGRP inhibitor like erenumab may slightly shift expectations, though switching within the class still works for many patients.

Lifestyle factors can mask or delay the drug's effect. Medication overuse headache (taking acute pain relievers more than 10 to 15 days per month), poor sleep, and high stress can all blunt or obscure galcanezumab's benefit even when the drug is working at a biological level.

How Do You Know If Emgality Is Working?

The benchmark used in clinical trials, and widely accepted by neurologists, is a 50% or greater reduction in monthly migraine days. That is the standard for a meaningful response.

But frequency is not the only thing worth tracking. Consider monitoring:

• Migraine severity on each attack (even if attacks still happen, are they milder?)
• Rescue medication use (are you reaching for triptans or OTC pain relievers less often?)
• Attack duration (shorter attacks can signal partial response)

A daily headache diary ties all of this together. It also helps you and your clinician distinguish Emgality's effect from concurrent changes like a new sleep schedule, stress reduction, or dietary adjustments that happened to coincide with starting the medication.

One common and understandable mistake is expecting complete migraine elimination. For most patients, galcanezumab is a meaningful reducer of frequency and severity, not a cure. Setting that expectation at the start helps you recognize genuine progress rather than feeling disappointed by a treatment that is, by clinical standards, working well.

Frequently Asked Questions

Can Emgality work after just one injection?

Yes, some patients notice fewer migraine days after their very first injection, especially with the 240 mg loading dose. Clinical trial data show statistically significant reductions as early as the first treatment period, though results vary considerably from person to person.

What should I do if galcanezumab is not working after 3 months?

Talk with your neurologist about reassessment before continuing indefinitely. Three months without any measurable improvement is a reasonable threshold to discuss switching strategies, adjusting other factors like medication overuse, or trying a different CGRP inhibitor.

Is galcanezumab faster-acting than erenumab or fremanezumab?

The loading dose may help galcanezumab reach therapeutic blood levels roughly one month sooner than some alternatives. However, head-to-head speed comparisons across CGRP inhibitors are limited, and individual response varies too much to declare one universally faster.

How long do you have to take Emgality before deciding if it works?

Most neurologists recommend a minimum of three months before concluding the medication has not worked. Stopping or switching before that point risks abandoning a treatment that may still be building toward its full effect over the typical response window.

Does the Emgality loading dose cause more side effects than the maintenance dose?

The loading dose involves two injections at once, so injection-site reactions may feel more noticeable. However, clinical trials did not find meaningfully higher rates of serious side effects with the 240 mg loading dose compared to the 120 mg maintenance dose.

The Bottom Line

For most people starting Emgality, an early signal often appears within the first month, with peak benefit usually arriving somewhere between months three and six. Patience and careful tracking are just as important as the medication itself, because natural migraine fluctuation can make it genuinely hard to tell what is the drug and what is chance. Keeping a headache diary, measuring rescue medication use, and aiming for that widely accepted benchmark of 50% or greater reduction in monthly migraine days will give you and your clinician the clearest picture. Doctronic, which has conducted more than 22 million AI consultations and offers free 24/7 access, can help you interpret your migraine diary, gauge whether your timeline looks on track, and prepare focused questions for your neurologist. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.